Vymedic

Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.

Analytics

Raised to Date: Raised: $202,770

Aggregate Commitments $
Platform

Netcapital

Start Date

09/25/2020

Close Date

03/24/2021

Min. Goal

$10,000

Max. Goal

$1,070,000

Min. Investment

$100

Security Type

Equity - Common

Funding Type

RegCF / RegD 506(C)

Series

Pre-Seed

Pre-Money Valuation

$20,000,000

Rolling Commitments $
Status
Funded
Reporting Date

03/31/2021

Days Remaining
Funded
% of Min. Goal

2,028%

% of Max. Goal

19%

Likelihood of Max
Funded
Avg. Daily Raise

$1,127

Momentum
Funded
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

Englewood, Colorado

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Business Type

Growth

Vymedic, with a post-money valuation of $23 million, is raising crowdfunding on NetCapital. The company has manufactured Vymune, a broad-spectrum antiviral, that beats other treatments in the suppression of influenza. Vymune is not strain-specific and activates the immune system against the illness. Cynthia Winning founded Vymedic in March 2020. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $1,070,000, and the proceeds will be used for hiring, manufacturing, and marketing. The product of Vymedic is patented, natural, and made up of amino acids, bioflavonoids, and co-factors. It is safe to use for children, elderly, pregnant women, and immunosuppressed individuals.
Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-46,788

$-45,688

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$2,032

$3,105

Accounts Receivable

$0

$0

Total Assets

$2,032

$3,105

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 09/25/2020
Log in or create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Staff Picks (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including Merlin ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by Merlin ratings
Company specific Merlin rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Ratings

Analyst Report

Other Deals

Cheers on StartEngine

Alcohol consumption is one of the oldest human practices on record. A study released in…

RegCF
EnGen Bio on Wefunder

COVID-19 has brought the world’s attention to vaccine development. In April 2021, a record 4

RegCF
Audubon Bioscience on MicroVentures

In 2020 alone, companies produced, tested, and began to produce a vaccine for a completely new virus on…

RegCF
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Vymedic on NetCapital
Follow company
Follow Vymedic on NetCapital
Want to learn more about Vymedic?
Join the Pre-IPO Market’s #1 Ratings & Analytics Service FREE for 7 days.
Yes! I want to start my free trial.
Already a member? Log in here.